BioCentury | Sep 26, 2020
Finance

Data Bytes: oncology pair shines in NASDAQ debut as queue swells

...to $26.20 Friday, boosting its valuation to $1.1 billion. That biotech has two clinical programs targeting PRMT5.The...
...earlier in the day, settling $0.50 above its offering price by Friday’s close.  TARGETSPRMT5Protein arginine methyltransferase 5 Paul...
BioCentury | Aug 27, 2020
Distillery Therapeutics

Promoting expression of immune targets IFI16 and NLRC5 for melanoma

...the expression of immune genes IFI16 and NLRC5 directly, or indirectly by inhibiting epigenetic protein PRMT5...
...of PRMT5 correlated with prolonged survival. In a mouse model of melanoma, an shRNA against PRMT5...
...inhibited tumor growth. Also in mice, an anti-PD-1 mAb in combination with the PRMT5-targeting shRNA or PRMT5...
BioCentury | Aug 26, 2020
Deals

Aug. 25 Quick Takes: A slew of private financings led by Connect’s $115M series C; plus BMS-Forbius, Takeda deals, Bio-Thera-BeiGene and adds to HKSE, NASDAQ queues

Connect raises $115M C round, eyes pivotal trialsRA Capital’s Derek DiRocco will join the board of Suzhou Connect Biopharmaceuticals Ltd. after the firm led the Chinese biotech’s $115 million series C round.  Additional new investors Lilly...
BioCentury | Aug 29, 2019
Distillery Therapeutics

Boosting cancer sensitivity to CDK4, CDK6 inhibitors by inhibiting the PRMT5-MDM4 axis

...DISEASE CATEGORY: Cancer INDICATION: Melanoma; breast cancer; esophageal cancer; pancreatic cancer Inhibiting the PRMT5-MDM4 axis could...
...PRMT5 inhibitor GSK3326595. Treatment with GSK3326595 or an shRNA against MDM4, a downstream mediator of PRMT5...
...and pancreatic cancers compared with either agent alone. Epizyme Inc. and GlaxoSmithKline plc have the PRMT5...
BioCentury | Jun 28, 2019
Preclinical News

June 28 Preclinical Quick Takes: BioNTech targets pancreatitis; plus new targets for HIV and more

Anti-glycan mAb licensed by BioNTech could prevent pancreatitis A Science study from Cold Spring Harbor Laboratory suggests the glycan CA19.9 (sialyl Lewis A), long known as a biomarker of pancreatic disease, actively drives the progression...
BioCentury | Jun 12, 2019
Financial News

OrbiMed-backed Prelude raises $60M to take PRMT5 program through clinical POC

...in new series B funding, Prelude hopes to obtain clinical proof-of-concept data for its lead PRMT5...
...said Prelude has developed molecules internally using its structure-based design techniques. The lead inhibitor of protein arginine methyltransferase 5 (PRMT5)...
...target PRMTs, but he declined to give details. BioCentury's BCIQ database lists only one other PRMT5...
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
BioCentury | Dec 6, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: November 2018

New Therapeutic Targets and Biomarkers: November 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during November. Therapeutic targets are defined as any protein, gene or other molecule...
BioCentury | Nov 6, 2018
Distillery Therapeutics

Cancer

INDICATION: Brain cancer Patient sample, cell culture and mouse studies suggest inhibiting PRMT2 could help treat glioblastoma multiforme (GBM). In GBM patients, high tumor levels of PRMT2 were associated with poor survival. In two human...
BioCentury | Nov 2, 2018
Targets & Mechanisms

FDA’s pediatric target picks

FDA is looking ahead of industry in its guideline on targets for pediatric oncology, which includes more than 50 not yet in company pipelines in a list of over 220 the agency has its eye...
Items per page:
1 - 10 of 27